New Antifungal Drug Candidate Shows Early Promise

Elion Therapeutics presents initial clinical data for a new antifungal aimed at reducing common treatment side effects.

Updated on Oct. 21, 2026 in Diseases — General

Isometric editorial illustration of a medical vial and pipette on a lab surface, representing pharmaceutical research on antifungal medication. — Elion Therapeutics is presenting Phase 2 clinical data for turletricin, an experimental antifungal drug designed to reduce toxic side effects. AI Illustration. Upload story photo >

Live Poll

Do you believe the clinical benefits of new medicines justify the risks of potential side effects?

Elion Therapeutics is presenting new clinical trial data on the antifungal drug candidate turletricin at the IDWeek 2026 conference in Washington, D.C. This experimental medication is currently being studied as a potential treatment for invasive mould infections and cryptococcal meningitis.

Why it matters

Current systemic polyene antifungals are often limited by severe side effects including nephrotoxicity, anemia, and inflammatory reactions. Turletricin is designed to provide the same antifungal efficacy as traditional polyenes while potentially avoiding these toxicities.

Turletricin has been evaluated in 200 participants across three Phase 1 studies and ongoing Phase 2 trials. Results from these early-stage investigations, including cerebrospinal fluid fungal clearance data, are now being shared with the medical community to assess the drug's safety and efficacy.

The players

Elion Therapeutics

A Boston-based pharmaceutical company focused on the development of novel antifungal medications.

The details

Turletricin is a systemic polyene antifungal candidate developed to improve upon existing treatment options. Researchers utilized single-ascending-dose, multiple-ascending-dose, and renal impairment studies to gauge safety. The current Phase 2 study focuses on patients with HIV-related cryptococcal meningitis to measure how effectively the drug clears fungal presence from the cerebrospinal fluid.

October 22, 2026: Safety and pharmacokinetics poster presentation at 12:15 p.m.
October 23, 2026: Clinical pipeline and cryptococcal meningitis presentations.

Health Landscape

Fungal infections account for 3.8 million deaths annually worldwide, driving an urgent need for safer treatment alternatives. The development of turletricin follows a pattern set by the FDA's Qualified Infectious Disease Product designation for incentivizing research into urgent, unmet needs in infectious diseases.

These early-stage results are intended for clinicians and researchers evaluating new treatment pathways for severe systemic infections. Patients managing fungal infection risks should consult their physician regarding current standard-of-care options and participate in discussions about new clinical options.

The takeaway

While experimental drugs like turletricin aim to reduce the toxic side effects of current antifungal therapies, these findings are still in the early stages of investigation. Patients concerned about infection management should focus on maintaining communication with their infectious disease specialist.